Use of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes on Multiple Daily Injections Versus Continuous Subcutaneous Insulin Infusion Therapy: A prospective 6-month study
OBJECTIVE: To compare use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injection (MDI) therapy versus continuous subcutaneous insulin infusion (CSII) therapy for 6 months. RESEARCH DESIGN AND METHODS: Sixty type 1 diabetic adults with similar baseline character...
Gespeichert in:
| Veröffentlicht in: | Diabetes care 2011-03, Vol.34 (3), p.574-579 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 579 |
|---|---|
| container_issue | 3 |
| container_start_page | 574 |
| container_title | Diabetes care |
| container_volume | 34 |
| creator | Garg, Satish K Voelmle, Mary K Beatson, Christie R Miller, Hayley A Crew, Lauren B Freson, Brandon J Hazenfield, Rachel M |
| description | OBJECTIVE: To compare use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injection (MDI) therapy versus continuous subcutaneous insulin infusion (CSII) therapy for 6 months. RESEARCH DESIGN AND METHODS: Sixty type 1 diabetic adults with similar baseline characteristics, using either MDI (n = 30) or CSII (n = 30) therapy, were enrolled in this 6-month prospective study. Subjects were instructed to wear the DexCom SevenPLUS continuous glucose monitor at all times throughout the study. All subjects were initially blinded from the continuous glucose monitoring (CGM) glucose data. After 4 weeks of blinded CGM use, the CGM was unblinded, making glucose data available to the patient. The CGM remained in the unblinded state for the remainder of the study (20 weeks). Clinic visits occurred every 4 weeks, at which time A1C values were collected and CGM data were downloaded. RESULTS: Mean baseline (± SD) A1C was 7.61 (± 0.76) and 7.63 (± 0.68) for CSII and MDI, respectively (P > 0.05). Without any significant therapy change, A1C decrease at 12 weeks was similar in both groups (P = 0.03). When compared with the blinded phase, unblinded use of CGM was associated with similar but significant reductions in glycemic control and variability parameters. In addition, both therapy groups had similar changes in mean glucose and glucose variability indexes at 3 and 6 months (ITT analysis, P > 0.05). Predefined per protocol analysis (sensor use at least 6 days/week) showed greater improvement in time spent in target range glycemia, 3.9-10.0 mmol/L (70-180 mg/dL), in the CSII group. CONCLUSIONS: We conclude that CGM provides similar benefits in glucose control for patients using MDI or CSII therapy. |
| doi_str_mv | 10.2337/dc10-1852 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3041183</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A251630674</galeid><sourcerecordid>A251630674</sourcerecordid><originalsourceid>FETCH-LOGICAL-f451t-a01dab3eb9935d094c680fe8db8087b5e5b23eab03ed463367fa75e05f559c963</originalsourceid><addsrcrecordid>eNptktFu0zAUhiMEYmVwwQuABUJcZdhx7NhcIFUdjEqbuFgLl5HjnLSuXDvE8aQ-Ga-HqxbYUOULy8efv6Pzy1n2kuCLgtLqQ6sJzolgxaNsQiRlOWOleJxNMCllzqQszrJnIWwwxmUpxNPsrCBFJQgVk-zXMgDyHZp5NxoXfQzoykbtU_XGOzP6wbgVMg7dxmYDegzohxnXaLHrARF0aVQDIwTkHbqJdjS9BXSpjN2hudvjxruAvsMQkvdeiyTTcVQO9oe5C9GmDnPXxZAeoMUaBtXvPqIp6gcf-r3nDhDPt8mwRmGM7e559qRTNsCL436eLb98Xsy-5tffruaz6XXelYyMucKkVQ2FRqZYWixLzQXuQLSNwKJqGLCmoKAaTKEtOaW86lTFALOOMaklp-fZp4O3j80WWg1uHJSt-8Fs1bCrvTL1wxtn1vXK39UUl4QImgTvj4LB_4wQxnprggZrD9PXgpWMM1ntyTf_kRsfB5emSxCXuBACJ-jtAVopC7VxnU9d9V5ZTwtGOMW8KhOVn6BW4FKw1jvoTCo_4C9O8Gm1sDX65INX92P5m8efj5WAd0dABa1sNyinTfjHUZk4sRe9PnCd8rVaDYlZ3haYUExkyTkv6G-v8Oci</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>856902880</pqid></control><display><type>article</type><title>Use of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes on Multiple Daily Injections Versus Continuous Subcutaneous Insulin Infusion Therapy: A prospective 6-month study</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Garg, Satish K ; Voelmle, Mary K ; Beatson, Christie R ; Miller, Hayley A ; Crew, Lauren B ; Freson, Brandon J ; Hazenfield, Rachel M</creator><creatorcontrib>Garg, Satish K ; Voelmle, Mary K ; Beatson, Christie R ; Miller, Hayley A ; Crew, Lauren B ; Freson, Brandon J ; Hazenfield, Rachel M</creatorcontrib><description>OBJECTIVE: To compare use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injection (MDI) therapy versus continuous subcutaneous insulin infusion (CSII) therapy for 6 months. RESEARCH DESIGN AND METHODS: Sixty type 1 diabetic adults with similar baseline characteristics, using either MDI (n = 30) or CSII (n = 30) therapy, were enrolled in this 6-month prospective study. Subjects were instructed to wear the DexCom SevenPLUS continuous glucose monitor at all times throughout the study. All subjects were initially blinded from the continuous glucose monitoring (CGM) glucose data. After 4 weeks of blinded CGM use, the CGM was unblinded, making glucose data available to the patient. The CGM remained in the unblinded state for the remainder of the study (20 weeks). Clinic visits occurred every 4 weeks, at which time A1C values were collected and CGM data were downloaded. RESULTS: Mean baseline (± SD) A1C was 7.61 (± 0.76) and 7.63 (± 0.68) for CSII and MDI, respectively (P > 0.05). Without any significant therapy change, A1C decrease at 12 weeks was similar in both groups (P = 0.03). When compared with the blinded phase, unblinded use of CGM was associated with similar but significant reductions in glycemic control and variability parameters. In addition, both therapy groups had similar changes in mean glucose and glucose variability indexes at 3 and 6 months (ITT analysis, P > 0.05). Predefined per protocol analysis (sensor use at least 6 days/week) showed greater improvement in time spent in target range glycemia, 3.9-10.0 mmol/L (70-180 mg/dL), in the CSII group. CONCLUSIONS: We conclude that CGM provides similar benefits in glucose control for patients using MDI or CSII therapy.</description><identifier>ISSN: 0149-5992</identifier><identifier>EISSN: 1935-5548</identifier><identifier>DOI: 10.2337/dc10-1852</identifier><identifier>PMID: 21278138</identifier><identifier>CODEN: DICAD2</identifier><language>eng</language><publisher>Alexandria, VA: American Diabetes Association</publisher><subject>Adult ; Biological and medical sciences ; Blood Glucose - metabolism ; Blood sugar monitoring ; Care and treatment ; Colleges & universities ; Dextrose ; Diabetes ; Diabetes Mellitus, Type 1 - blood ; Diabetes Mellitus, Type 1 - drug therapy ; Diabetes. Impaired glucose tolerance ; Drug Administration Schedule ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Female ; Glucose ; Humans ; Hyperglycemia ; Hypoglycemia ; Infusions, Subcutaneous - methods ; Injections, Subcutaneous - methods ; Insulin ; Insulin - administration & dosage ; Insulin - therapeutic use ; Male ; Medical sciences ; Metabolic diseases ; Middle Aged ; Miscellaneous ; Original Research ; Prospective Studies ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Type 1 diabetes</subject><ispartof>Diabetes care, 2011-03, Vol.34 (3), p.574-579</ispartof><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2011 American Diabetes Association</rights><rights>Copyright American Diabetes Association Mar 2011</rights><rights>2011 by the American Diabetes Association. 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,781,785,886,27929,27930</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23978184$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21278138$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Garg, Satish K</creatorcontrib><creatorcontrib>Voelmle, Mary K</creatorcontrib><creatorcontrib>Beatson, Christie R</creatorcontrib><creatorcontrib>Miller, Hayley A</creatorcontrib><creatorcontrib>Crew, Lauren B</creatorcontrib><creatorcontrib>Freson, Brandon J</creatorcontrib><creatorcontrib>Hazenfield, Rachel M</creatorcontrib><title>Use of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes on Multiple Daily Injections Versus Continuous Subcutaneous Insulin Infusion Therapy: A prospective 6-month study</title><title>Diabetes care</title><addtitle>Diabetes Care</addtitle><description>OBJECTIVE: To compare use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injection (MDI) therapy versus continuous subcutaneous insulin infusion (CSII) therapy for 6 months. RESEARCH DESIGN AND METHODS: Sixty type 1 diabetic adults with similar baseline characteristics, using either MDI (n = 30) or CSII (n = 30) therapy, were enrolled in this 6-month prospective study. Subjects were instructed to wear the DexCom SevenPLUS continuous glucose monitor at all times throughout the study. All subjects were initially blinded from the continuous glucose monitoring (CGM) glucose data. After 4 weeks of blinded CGM use, the CGM was unblinded, making glucose data available to the patient. The CGM remained in the unblinded state for the remainder of the study (20 weeks). Clinic visits occurred every 4 weeks, at which time A1C values were collected and CGM data were downloaded. RESULTS: Mean baseline (± SD) A1C was 7.61 (± 0.76) and 7.63 (± 0.68) for CSII and MDI, respectively (P > 0.05). Without any significant therapy change, A1C decrease at 12 weeks was similar in both groups (P = 0.03). When compared with the blinded phase, unblinded use of CGM was associated with similar but significant reductions in glycemic control and variability parameters. In addition, both therapy groups had similar changes in mean glucose and glucose variability indexes at 3 and 6 months (ITT analysis, P > 0.05). Predefined per protocol analysis (sensor use at least 6 days/week) showed greater improvement in time spent in target range glycemia, 3.9-10.0 mmol/L (70-180 mg/dL), in the CSII group. CONCLUSIONS: We conclude that CGM provides similar benefits in glucose control for patients using MDI or CSII therapy.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Blood Glucose - metabolism</subject><subject>Blood sugar monitoring</subject><subject>Care and treatment</subject><subject>Colleges & universities</subject><subject>Dextrose</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 1 - blood</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Drug Administration Schedule</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Female</subject><subject>Glucose</subject><subject>Humans</subject><subject>Hyperglycemia</subject><subject>Hypoglycemia</subject><subject>Infusions, Subcutaneous - methods</subject><subject>Injections, Subcutaneous - methods</subject><subject>Insulin</subject><subject>Insulin - administration & dosage</subject><subject>Insulin - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Original Research</subject><subject>Prospective Studies</subject><subject>Public health. Hygiene</subject><subject>Public health. Hygiene-occupational medicine</subject><subject>Type 1 diabetes</subject><issn>0149-5992</issn><issn>1935-5548</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptktFu0zAUhiMEYmVwwQuABUJcZdhx7NhcIFUdjEqbuFgLl5HjnLSuXDvE8aQ-Ga-HqxbYUOULy8efv6Pzy1n2kuCLgtLqQ6sJzolgxaNsQiRlOWOleJxNMCllzqQszrJnIWwwxmUpxNPsrCBFJQgVk-zXMgDyHZp5NxoXfQzoykbtU_XGOzP6wbgVMg7dxmYDegzohxnXaLHrARF0aVQDIwTkHbqJdjS9BXSpjN2hudvjxruAvsMQkvdeiyTTcVQO9oe5C9GmDnPXxZAeoMUaBtXvPqIp6gcf-r3nDhDPt8mwRmGM7e559qRTNsCL436eLb98Xsy-5tffruaz6XXelYyMucKkVQ2FRqZYWixLzQXuQLSNwKJqGLCmoKAaTKEtOaW86lTFALOOMaklp-fZp4O3j80WWg1uHJSt-8Fs1bCrvTL1wxtn1vXK39UUl4QImgTvj4LB_4wQxnprggZrD9PXgpWMM1ntyTf_kRsfB5emSxCXuBACJ-jtAVopC7VxnU9d9V5ZTwtGOMW8KhOVn6BW4FKw1jvoTCo_4C9O8Gm1sDX65INX92P5m8efj5WAd0dABa1sNyinTfjHUZk4sRe9PnCd8rVaDYlZ3haYUExkyTkv6G-v8Oci</recordid><startdate>20110301</startdate><enddate>20110301</enddate><creator>Garg, Satish K</creator><creator>Voelmle, Mary K</creator><creator>Beatson, Christie R</creator><creator>Miller, Hayley A</creator><creator>Crew, Lauren B</creator><creator>Freson, Brandon J</creator><creator>Hazenfield, Rachel M</creator><general>American Diabetes Association</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0K</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20110301</creationdate><title>Use of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes on Multiple Daily Injections Versus Continuous Subcutaneous Insulin Infusion Therapy: A prospective 6-month study</title><author>Garg, Satish K ; Voelmle, Mary K ; Beatson, Christie R ; Miller, Hayley A ; Crew, Lauren B ; Freson, Brandon J ; Hazenfield, Rachel M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-f451t-a01dab3eb9935d094c680fe8db8087b5e5b23eab03ed463367fa75e05f559c963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Blood Glucose - metabolism</topic><topic>Blood sugar monitoring</topic><topic>Care and treatment</topic><topic>Colleges & universities</topic><topic>Dextrose</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 1 - blood</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Drug Administration Schedule</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Female</topic><topic>Glucose</topic><topic>Humans</topic><topic>Hyperglycemia</topic><topic>Hypoglycemia</topic><topic>Infusions, Subcutaneous - methods</topic><topic>Injections, Subcutaneous - methods</topic><topic>Insulin</topic><topic>Insulin - administration & dosage</topic><topic>Insulin - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Original Research</topic><topic>Prospective Studies</topic><topic>Public health. Hygiene</topic><topic>Public health. Hygiene-occupational medicine</topic><topic>Type 1 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Garg, Satish K</creatorcontrib><creatorcontrib>Voelmle, Mary K</creatorcontrib><creatorcontrib>Beatson, Christie R</creatorcontrib><creatorcontrib>Miller, Hayley A</creatorcontrib><creatorcontrib>Crew, Lauren B</creatorcontrib><creatorcontrib>Freson, Brandon J</creatorcontrib><creatorcontrib>Hazenfield, Rachel M</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Agricultural Science Database</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetes care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garg, Satish K</au><au>Voelmle, Mary K</au><au>Beatson, Christie R</au><au>Miller, Hayley A</au><au>Crew, Lauren B</au><au>Freson, Brandon J</au><au>Hazenfield, Rachel M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes on Multiple Daily Injections Versus Continuous Subcutaneous Insulin Infusion Therapy: A prospective 6-month study</atitle><jtitle>Diabetes care</jtitle><addtitle>Diabetes Care</addtitle><date>2011-03-01</date><risdate>2011</risdate><volume>34</volume><issue>3</issue><spage>574</spage><epage>579</epage><pages>574-579</pages><issn>0149-5992</issn><eissn>1935-5548</eissn><coden>DICAD2</coden><abstract>OBJECTIVE: To compare use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injection (MDI) therapy versus continuous subcutaneous insulin infusion (CSII) therapy for 6 months. RESEARCH DESIGN AND METHODS: Sixty type 1 diabetic adults with similar baseline characteristics, using either MDI (n = 30) or CSII (n = 30) therapy, were enrolled in this 6-month prospective study. Subjects were instructed to wear the DexCom SevenPLUS continuous glucose monitor at all times throughout the study. All subjects were initially blinded from the continuous glucose monitoring (CGM) glucose data. After 4 weeks of blinded CGM use, the CGM was unblinded, making glucose data available to the patient. The CGM remained in the unblinded state for the remainder of the study (20 weeks). Clinic visits occurred every 4 weeks, at which time A1C values were collected and CGM data were downloaded. RESULTS: Mean baseline (± SD) A1C was 7.61 (± 0.76) and 7.63 (± 0.68) for CSII and MDI, respectively (P > 0.05). Without any significant therapy change, A1C decrease at 12 weeks was similar in both groups (P = 0.03). When compared with the blinded phase, unblinded use of CGM was associated with similar but significant reductions in glycemic control and variability parameters. In addition, both therapy groups had similar changes in mean glucose and glucose variability indexes at 3 and 6 months (ITT analysis, P > 0.05). Predefined per protocol analysis (sensor use at least 6 days/week) showed greater improvement in time spent in target range glycemia, 3.9-10.0 mmol/L (70-180 mg/dL), in the CSII group. CONCLUSIONS: We conclude that CGM provides similar benefits in glucose control for patients using MDI or CSII therapy.</abstract><cop>Alexandria, VA</cop><pub>American Diabetes Association</pub><pmid>21278138</pmid><doi>10.2337/dc10-1852</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0149-5992 |
| ispartof | Diabetes care, 2011-03, Vol.34 (3), p.574-579 |
| issn | 0149-5992 1935-5548 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3041183 |
| source | MEDLINE; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Biological and medical sciences Blood Glucose - metabolism Blood sugar monitoring Care and treatment Colleges & universities Dextrose Diabetes Diabetes Mellitus, Type 1 - blood Diabetes Mellitus, Type 1 - drug therapy Diabetes. Impaired glucose tolerance Drug Administration Schedule Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Female Glucose Humans Hyperglycemia Hypoglycemia Infusions, Subcutaneous - methods Injections, Subcutaneous - methods Insulin Insulin - administration & dosage Insulin - therapeutic use Male Medical sciences Metabolic diseases Middle Aged Miscellaneous Original Research Prospective Studies Public health. Hygiene Public health. Hygiene-occupational medicine Type 1 diabetes |
| title | Use of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes on Multiple Daily Injections Versus Continuous Subcutaneous Insulin Infusion Therapy: A prospective 6-month study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T20%3A23%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20Continuous%20Glucose%20Monitoring%20in%20Subjects%20With%20Type%201%20Diabetes%20on%20Multiple%20Daily%20Injections%20Versus%20Continuous%20Subcutaneous%20Insulin%20Infusion%20Therapy:%20A%20prospective%206-month%20study&rft.jtitle=Diabetes%20care&rft.au=Garg,%20Satish%20K&rft.date=2011-03-01&rft.volume=34&rft.issue=3&rft.spage=574&rft.epage=579&rft.pages=574-579&rft.issn=0149-5992&rft.eissn=1935-5548&rft.coden=DICAD2&rft_id=info:doi/10.2337/dc10-1852&rft_dat=%3Cgale_pubme%3EA251630674%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=856902880&rft_id=info:pmid/21278138&rft_galeid=A251630674&rfr_iscdi=true |